Equities research analysts forecast that Orthopediatrics Corp (NASDAQ:KIDS) will announce sales of $14.19 million for the current quarter, according to Zacks. Three analysts have provided estimates for Orthopediatrics’ earnings, with the highest sales estimate coming in at $14.20 million and the lowest estimate coming in at $14.18 million. Orthopediatrics posted sales of $11.68 million during the same quarter last year, which suggests a positive year-over-year growth rate of 21.5%. The company is expected to issue its next earnings report on Wednesday, March 6th.

On average, analysts expect that Orthopediatrics will report full-year sales of $57.19 million for the current fiscal year, with estimates ranging from $57.17 million to $57.20 million. For the next fiscal year, analysts forecast that the company will post sales of $69.47 million, with estimates ranging from $69.00 million to $69.80 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Wednesday, October 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). The firm had revenue of $15.82 million for the quarter, compared to analyst estimates of $15.19 million. Orthopediatrics had a negative net margin of 55.97% and a negative return on equity of 65.26%. The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.70) earnings per share.

Several equities research analysts have recently issued reports on the company. BidaskClub upgraded Orthopediatrics from a “sell” rating to a “hold” rating in a report on Wednesday, November 28th. Zacks Investment Research lowered Orthopediatrics from a “buy” rating to a “hold” rating in a report on Saturday, November 3rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.33.

In related news, Director Kevin Unger sold 1,000 shares of the business’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $33.22, for a total value of $33,220.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 46.10% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new position in shares of Orthopediatrics during the second quarter worth about $126,000. Millennium Management LLC acquired a new position in Orthopediatrics during the first quarter valued at approximately $172,000. Rhumbline Advisers bought a new stake in Orthopediatrics in the third quarter valued at approximately $207,000. Renaissance Technologies LLC bought a new stake in Orthopediatrics in the third quarter valued at approximately $242,000. Finally, Regal Investment Advisors LLC bought a new position in Orthopediatrics during the 3rd quarter worth $246,000. Institutional investors own 40.42% of the company’s stock.

Shares of Orthopediatrics stock opened at $29.95 on Thursday. The stock has a market cap of $383.70 million, a PE ratio of -5.25 and a beta of 0.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.67 and a quick ratio of 3.23. Orthopediatrics has a 52-week low of $14.00 and a 52-week high of $39.81.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

See Also: Dollar Cost Averaging

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.